期刊
BRITISH JOURNAL OF CANCER
卷 117, 期 8, 页码 1241-1245出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/bjc.2017.282
关键词
multiple myeloma; resistin; prospective cohorts
类别
资金
- Intramural Research Program of the National Institutes of Health, National Cancer Institute
- Terry Fox Foundation, Vancouver, Canada
- Intramural Research Program of the U.S. National Cancer Institute, National Institutes of Health
- U.S. Public Health Service from National Cancer Institute, Department of Health and Human Services [HHSN261201500005C]
- NIH/NCI extramural grants [K07 CA115687, R01 CA127435]
- NCI Intramural Research Program
- [R21 CA198239]
Background: Resistin is a polypeptide hormone secreted by adipose tissue. A prior hospital-based case-control study reported serum resistin levels to be inversely associated with risk of multiple myeloma (MM). To date, this association has not been investigated prospectively. Methods: We measured resistin concentrations for pre-diagnosis peripheral blood samples from 178 MM cases and 358 individually matched controls from three cohorts participating in the MM cohort consortium. Results: In overall analyses, higher resistin levels were weakly associated with reduced MM risk. For men, we observed a statistically significant inverse association between resistin levels and MM (odds ratio, 0.44; 95% confidence interval (CI) 0.24-0.83 and 0.54; 95% CI 0.29-0.99, for the third and fourth quartiles, respectively, vs the lowest quartile; P-trend = 0.03). No association was observed for women. Conclusions: This study provides the first prospective evidence that low circulating resistin levels may be associated with an increased risk of MM, particularly for men.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据